Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Removing Lipid Droplets Improves Fat Transplantation Outcomes in a Mouse Model through Suppressing Pro-fibrotic Macrophage Responses.

Niu X., He Y., Huang X., Gao J., Lu F., Chang Q.

Animal Study on Chronic Inflammation, published in Aesthetic Plast Surg (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Aesthetic Plast Surg (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41703064
DOI
10.1007/s00266-025-05526-z

Abstract (original English)

The clinical efficacy and predictability of autologous fat grafting are frequently undermined by uncontrolled fibrosis and oil cyst formation. While lipid droplets (LDs) metabolic imbalance is recognized as a critical factor influencing graft outcomes, the underlying mechanisms linking LDs to adverse tissue remodeling remain poorly understood. This study aimed to elucidate the mechanistic impact of extracellular LDs on fat graft outcomes in a murine model, with a specific focus on their role in modulating macrophage-mediated inflammation and fibrosis. Fat grafts were transplanted into C57BL/6J mice and divided into two groups: an oil-retained group (control) and an oil-removed group (intervention). Grafts were harvested at serial timepoints (2-12 weeks) for comprehensive analysis, including histopathology (H&E, Masson's trichrome), quantitative PCR for inflammatory and fibrotic markers (TNF-α, IL-1β, IL-6, TGF-β), and immunofluorescence staining to assess macrophage polarization (CD86 for M1, CD206 for M2). The presence of excess extracellular LDs acted as a potent inflammatory trigger, driving a significant upregulation of pro-inflammatory cytokines, including TNF-α (2.4-fold), IL-6 (1.9-fold), and IL-1β (2.8-fold). This pro-inflammatory microenvironment was associated with a dominant M1 macrophage phenotype. Conversely, the preoperative removal of LDs fundamentally altered th

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMiceMacrophagesMice, Inbred C57BLFibrosisAdipose TissueLipid DropletsDisease Models, AnimalGraft SurvivalMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research